La chaîne d'options affiche les données clés des options sur actions de Compass Pathways à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Compass Pathways..

Compass Pathways (NASDAQ:CMPS) Stock, Chaîne d'Options

COMPASS PATHWAYS PLC

Compass Pathways

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

COMPASS Pathways Plc - American Depository Shares

Compass Pathways PLC

Press Releases

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

CMPS

Absci

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Celcuity

Checkpoint Therapeutics, Inc. - Common Stock

Checkpoint Therapeutics

Emergent BioSolutions

Erasca

Heron Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Myriad Genetics

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Organogenesis Holdings

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Oruka Therapeutics

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Rezolute

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Comments

Compass Pathways

Compass Pathways (CMPS) Options

Compass Pathways (NASDAQ:CMPS) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL